Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4691 - Downregulation of BRCA1 protein in clear cell renal cellular carcinoma.


11 Sep 2017


Poster display session


Translational Research;  Renal Cell Cancer


Elzbieta Sarnowska


Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391


E. Sarnowska1, N. Rusetska1, M. Szymanski2, I. Jancewicz1, M. Chmielarczyk1, R. Konopinski1, M. Leszczynski1, A. Chrzan3, M. Ligaj3, A. Maassen4, T. Sarnowski5, J. Siedlecki1

Author affiliations

  • 1 Department Of Molecular And Translational Oncology, Maria Sklodowska-Curie Cancer Center, 02-781 - Warsaw/PL
  • 2 Department Of Urology, Maria Skłodowska-Curie Cancer Center, 02-781 - Warsaw/PL
  • 3 Department Of Pathology, Maria Skłodowska-Curie Cancer Center, 02-781 - Warsaw/PL
  • 4 Department Of Protein Biosynthesis, Institute of Biochemistry and Biophysics, 02-106106 - Warsaw/PL
  • 5 Protein Biosyntesis, Instytut of Biochemy and Biophysic, 02-106 - Warsaw/PL


Abstract 4691


Around 75% of renal cancer in adult kidney is clear cell renal cellular carcinoma (ccRCC). This type of cancer is characterized by lipids overacumulation and mutations in VHL (around 90% cases), BAP1 and PBRM1 genes as well as stabilization of HIF1α transcription factor. Additionally, metabolic switch to aerobic glycolysis and aberration in TCA cycle was observed in ccRCC independently on the stage of the disease. Moreover, the mTOR pathway hyperactivation and downregulation of AMPK pathway featured the ccRCC. This type of cancer is highly resistant to classical chemotherapy. BRCA1 is tumor suppressor gene, mutation in this gene is associated with breast and ovarian cancer. BRCA1 is a protein involved in DNA repair and apoptosis also interacts with BRG1 – core subunit of SWI/SNF chromatin remodeling complex. BRCA1 is transcribed from bidirectional promoter together with NBR2 – lncRNA. Interestingly, NBR2 interacts with AMPK and is downregulated in ccRCC. CTCF is a protein which binds Topologicaly Associated Domains, and CTCF binding site was found in BRCA1/NBR2 promoter region.


Immunohistochemistry (IHC) on paraffin embedded clinical samples for BRCA1 and BRG1 core subunit of SWI/SNF complex, comparative transcriptomic study, co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (ChIP) method were used in this work.


In this study we found downregulation of BRCA1 and BRG1 proteins in ccRCC patient samples independently on stage of the disease. Interestingly, downregulation of BRG1 was more severe in samples with strong lymphocyte infiltration. By contrast, downregulation at the transcript level was observed for BRG1 encoding gene but not for BRCA1. BRG1 and CTCF co-precipitated from cancer cells, indicating the existence of co-interaction between CTCF, BRG1 and BRCA1 proteins. Additionally, overexpression of BRG1 caused increased expression of CTCF in human cells. We also found that BRG1 targets both CTCF and BRCA1 genes.


BRCA1, BRG1 and CTCF module is dysregulated in ccRCC cells independently on Fuhrman grade and stage of the disease. This missregulation can have a brought spectrum of changes including 3D chromatin structure, transcription, epigenetic and others.

Clinical trial identification

Legal entity responsible for the study

Elzbieta Sarnowska


This work was supported by grant from National Science Center No UMO–2013/11/B/NZ2/00132


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.